NCT02829918 2026-03-11
Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
Clinical Trials
6 trialsNCT03785873 2026-02-13
Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer
University of Michigan Rogel Cancer Center
Phase 1/2 Completed
NCT04057365 2025-08-13
Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)
Massachusetts General Hospital
Phase 2 Terminated
NCT03639935 2025-06-03
Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT03447470 2025-01-29
Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies
Redx Pharma Ltd
Phase 1 Completed
NCT03101566 2022-10-28
Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer
University of Michigan Rogel Cancer Center
Phase 2 Completed